A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 03 Feb 2017 Status changed from recruiting to completed.
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 New trial record